Management in Health, Vol 13, No 3 (2009)

Font Size:  Small  Medium  Large

Cost-Effectiveness Evaluation of Tocilizumab in Romanian Setting

Ioan Ancuţa, Simona Baculea, Monika Szkultecka-Debek

Abstract


The aim of the study is to evaluate cost-effectiveness of tocilizumab for the treatment of Rheumatoid Arthritis in patients with traditional DMARD inadequate response (DMARD-IR).
Methodology compares two alternatives: sequence of treatment including either infliximab, etanercept or adalimumab, followed by rituximab, and sequence of treatment including tocilizumab as first agent in the treatment sequence, followed by rituximab.
Data used is from clinical trials, and also local cost data for direct and indirect costs of treatment sequences. Time horizon is life-time period of each individual.
The type of evaluation is cost-utility, and the perspective is that of the payer (National Health Insurance House) as well as of the society. The Incremental Cost-Effectiveness Ratio is 58,866 Rol per QALY gained, which compares favorably with other treatments reimbursed by the National Health Insurance House. Results were tested using a one-way sensitivity analysis.

Keywords: cost-effectiveness analysis, rheumatoid arthritis, treatment using tociluzumab.

Content temporarely available only in Romanian.


Full Text: HTML PDF

Journal published by SNSPMS